Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), are being administered worldwide. A successful, safe and targeted therapeutic drug to treat this infection is yet to emerge.
Convalescent plasma, repurposed antivirals, neutralizing monoclonal antibodies, and highly selected nanobodies (Nbs) and multivalent forms are some of the innovative therapeutics tried against this virus.
